Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience

Abstract Background Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales. Results A total of 130 patients received a PP (median age: 62.5 years [IQR: 58–69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5–7]). Median follow-up was 6.3 years [IQR: 4–9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p = 0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction. Conclusions PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.

Download Full-text

Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction

Korean Journal of Urology ◽

10.4111/kju.2015.56.6.461 ◽

2015 ◽

Vol 56 (6) ◽

pp. 461 ◽

Cited By ~ 22

Author(s):

Yoon Seob Ji ◽

Young Hwii Ko ◽

Phil Hyun Song ◽

Ki Hak Moon

Keyword(s):

Patient Satisfaction ◽

Erectile Dysfunction ◽

Penile Prosthesis ◽

Term Survival ◽

Long Term Survival ◽

Inflatable Penile Prosthesis

Download Full-text

Long-term results after early definitive surgical correction of complete atrioventricular septal defect with two patch technique and complete cleft closure: ten years single centre experience

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0029-1246846 ◽

2010 ◽

Vol 58 (S 01) ◽

Author(s):

F Bakhtiary ◽

J Januschek ◽

T Walther ◽

M Borger ◽

FW Mohr ◽

...

Keyword(s):

Septal Defect ◽

Atrioventricular Septal Defect ◽

Surgical Correction ◽

Long Term Results ◽

Single Centre ◽

Single Centre Experience ◽

Cleft Closure ◽

Patch Technique ◽

Complete Atrioventricular

Download Full-text

Faculty Opinions recommendation of Long-term outcome following pneumatic dilatation as initial therapy for idiopathic achalasia: an 18-year single-centre experience.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718113642.793484094 ◽

2013 ◽

Author(s):

Rebecca Fitzgerald

Keyword(s):

Initial Therapy ◽

Pneumatic Dilatation ◽

Single Centre ◽

Term Outcome ◽

Long Term Outcome ◽

Idiopathic Achalasia ◽

Single Centre Experience

Download Full-text

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience

Journal of Endocrinological Investigation ◽

10.1007/s40618-021-01562-z ◽

2021 ◽

Author(s):

E. Sala ◽

G. Carosi ◽

G. Del Sindaco ◽

R. Mungari ◽

A. Cremaschi ◽

...

Keyword(s):

Median Time ◽

Pituitary Surgery ◽

Somatostatin Analogues ◽

Exclusion Criterion ◽

Single Centre ◽

Disease Evolution ◽

Single Centre Experience ◽

Pituitary Irradiation

Abstract Purpose A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has been described in some series. Our aim was to update the disease evolution after SAs withdrawal in a cohort of acromegalic patients. Methods We retrospectively evaluated 21 acromegalic patients previously included in a multicentre study (Ronchi et al. 2008), updating data at the last follow-up. We added further 8 patients selected for SAs withdrawal between 2008–2018. Pituitary irradiation represented an exclusion criterion. The withdrawal was suggested after at least 9 months of clinical and hormonal disease control. Clinical and biochemical data prior and after SAs withdrawal were analysed. Results In the whole cohort (29 patients) mean age was 50 ± 14.9 years and 72.4% were females. In 69% pituitary surgery was previously performed. Overall, the median time of treatment before SAs withdrawal was 53 months (IQR = 24–84). At the last follow up in 2019, 23/29 patients (79.3%) had a disease relapse after a median time of 6 months (interquartile range or IQR = 3–12) from the drug suspension, while 6/29 (20.7%) were still on remission after 120 months (IQR = 66–150). IGF-1 levels were significantly lower before withdrawal in patients with persistent remission compared to relapsing ones (IGF-1 SDS: -1.5 ± 0.6 vs -0.11 ± 1, p = 0.01). We did not observe any other difference between patients with and without relapse, including SAs formulation, dosage and treatment duration. Conclusion A successful withdrawal of SAs is possible in a subset of well-controlled acromegalic patients and it challenges the concept that medical therapy is a lifelong requirement.

Download Full-text

Long-term Implications of Pacemaker Insertion in Younger Adults: A Single Centre Experience

Heart Lung and Circulation ◽

10.1016/j.hlc.2021.06.153 ◽

2021 ◽

Vol 30 ◽

pp. S160

Author(s):

A. Shirwaiker ◽

J. William ◽

J. Mariani ◽

P. Kistler ◽

H. Patel ◽

...

Keyword(s):

Single Centre ◽

Younger Adults ◽

Single Centre Experience ◽

Pacemaker Insertion

Download Full-text

907 Reduction of Nasal Fractures During COVID-19: A Single-Centre Experience

British Journal of Surgery ◽

10.1093/bjs/znab134.096 ◽

2021 ◽

Vol 108 (Supplement_2) ◽

Author(s):

T Crotty ◽

M Corbett ◽

T Hussain ◽

A Diaconescu ◽

N Patil

Keyword(s):

Patient Satisfaction ◽

Prospective Study ◽

Local Anaesthetic ◽

Regional Anaesthesia ◽

Effective Alternative ◽

General Anaesthetic ◽

Single Centre ◽

Pain Scores ◽

Single Centre Experience ◽

Nasal Fractures

Abstract Introduction The utilization of local or regional anaesthesia for manipulation of nasal fractures (MNF) avoids the need for general anaesthetic (GA), and the risk associated with instrumentation of the airway during the COVID-19 pandemic. Furthermore, MNF under local anaesthetic (LA) provides similar results with regards to cosmesis and patient satisfaction. We present our experience of performing MNF under LA during the COVID-19 pandemic. Method A single-centre, prospective study of all patients undergoing MNF under LA was conducted (13th July/20–11thSeptember/20). Following reduction, pain scores and patient satisfaction surveys were administered. Results A total of 25 patients (M/F:16/9, median age, 25.6yr (14-52yr)) were enrolled. The majority of patients received either one or two instillations of LA (n = 19, 76%). Pain reported during the MNF procedure was 4.4/10, whilst pain during LA administration was reported as 3.2/10. 80% of patients felt instillation of LA was less painful than expected. 88% of respondents tolerated the LA well, and only 8% would have opted for general anaesthetic. 24 (96%) participants were happy with the cosmetic result. Discussion MNF under LA is a safe and effective alternative to MNF under GA. More literature is needed to define the best method of administering LA prior to performing MNF.

Download Full-text